Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Helen Ma, Owen A. O’Connor & Enrica Marchi. (2019) New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination. Expert Review of Hematology 12:3, pages 137-146.
Read now
Read now
Lisa Giulino-Roth. (2015) EZH2: a potential new target in T-cell lymphoma?. Leukemia & Lymphoma 56:7, pages 1924-1925.
Read now
Read now
Articles from other publishers (17)
Robert Stuver, Steven M. Horwitz & Zachary D. Epstein-Peterson. (2023) Treatment of Adult T-Cell Leukemia/Lymphoma: Established Paradigms and Emerging Directions. Current Treatment Options in Oncology 24:8, pages 948-964.
Crossref
Crossref
Robert Stuver & Alison J. Moskowitz. (2023) Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma. Cancers 15:3, pages 589.
Crossref
Crossref
Yuqin Song, Yanyan Liu, Zhi-Ming Li, Lanfang Li, Hang Su, Zhengming Jin, Xuelan Zuo, Jianyuan Wu, Hui Zhou, Kunyan Li, Chuan He, Jianfeng Zhou, Junyuan Qi, Siguo Hao, Zhen Cai, Yijing Li, Weiwei Wang, Xiaojing Zhang, Jianjun Zou & Jun Zhu. (2022) SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial. The Lancet Haematology 9:7, pages e493-e503.
Crossref
Crossref
Franziska Lea Schümann, Elisabeth Groß, Marcus Bauer, Christian Rohde, Sarah Sandmann, Denis Terziev, Lutz P. Müller, Guido Posern, Andreas Wienke, Falko Fend, Martin-Leo Hansmann, Wolfram Klapper, Andreas Rosenwald, Harald Stein, Martin Dugas, Carsten Müller-Tidow, Claudia Wickenhauser, Mascha Binder & Thomas Weber. (2021) Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas. Biomedicines 9:12, pages 1842.
Crossref
Crossref
H. Miles Prince, Jasmine Zain, Anas Younes, Sean Whittaker, Owen A. O'Connor & Sean Harrop. 2021. The Peripheral T‐Cell Lymphomas. The Peripheral T‐Cell Lymphomas
27
45
.
Ping Zhang & Mingzhi Zhang. (2020) Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. Clinical Epigenetics 12:1.
Crossref
Crossref
Huilai Zhang, Huijuan Lv, Xiaohui Jia, Ge Hu, Lingzhe Kong, Tingting Zhang, Linyu Li, Yi Pan, Qiongli Zhai, Bin Meng, Xi Wang, Huaqing Wang & Xianhuo Wang. (2019) Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T‑cell lymphoma. Oncology Letters.
Crossref
Crossref
Hui-Xiang Zhang, Ping-Lian Yang, En-Min Li & Li-Yan Xu. (2019) STAT3beta, a distinct isoform from STAT3. The International Journal of Biochemistry & Cell Biology 110, pages 130-139.
Crossref
Crossref
Xuejun Tian, Jie Xu & David M. Dorfman. (2019) Utility of Combined EZH2, p-ERK1/2, p-STAT, and MYC Expression in the Differential Diagnosis of EZH2-positive Hodgkin Lymphomas and Related Large B-Cell Lymphomas. American Journal of Surgical Pathology 43:1, pages 102-109.
Crossref
Crossref
Ambrus Gángó, Bence Bátai, Martin Varga, Dóra Kapczár, Gergő Papp, Márta Marschalkó, Enikő Kuroli, Tamás Schneider, Judit Csomor, András Matolcsy, Csaba Bödör & Ágota Szepesi. (2018) Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein. Virchows Archiv 473:4, pages 453-462.
Crossref
Crossref
Shengguo Yi, Jingru Sun, Lei Qiu, Wenjing Fu, Anqi Wang, Xiaoqing Liu, Yong Yang, Marshall E. Kadin, Ping Tu & Yang Wang. (2018) Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment. Journal of Investigative Dermatology 138:5, pages 1126-1136.
Crossref
Crossref
Xuejun Tian, Jie Xu, Christopher Fletcher, Jason L Hornick & David M Dorfman. (2018) Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling. Modern Pathology 31:4, pages 553-561.
Crossref
Crossref
Mark E. Issa, Farnaz Sedigheh Takhsha, Chandra Sekhar Chirumamilla, Claudina Perez-Novo, Wim Vanden Berghe & Muriel Cuendet. (2017) Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clinical Epigenetics 9:1.
Crossref
Crossref
David M. Dorfman, Elizabeth A. Morgan, Ashley Pelton & Christine Unitt. (2017) T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation. Human Pathology 65, pages 166-174.
Crossref
Crossref
Rebecca L. BoddickerGina L. Razidlo, Surendra DasariYu ZengGuangzhen HuRyan A. KnudsonPatricia T. GreippJaime I. DavilaSarah H. JohnsonJulie C. PorcherJames B. SmadbeckBruce W. EckloffDaniel D. Billadeau, Paul J. KurtinMark A. McNiven, Brian K. LinkStephen M. Ansell, James R. Cerhan, Yan W. Asmann, George VasmatzisAndrew L. Feldman. (2016) Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood 128:9, pages 1234-1245.
Crossref
Crossref
Xuejun Tian, Ashley Pelton, Ali Shahsafaei & David M Dorfman. (2016) Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas. Modern Pathology 29:9, pages 1050-1057.
Crossref
Crossref
Monika Maleszewska, Byambasuren Vanchin, Martin C. Harmsen & Guido Krenning. (2015) The decrease in histone methyltransferase EZH2 in response to fluid shear stress alters endothelial gene expression and promotes quiescence. Angiogenesis 19:1, pages 9-24.
Crossref
Crossref